The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer.
The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.
Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.